<DOC>
	<DOCNO>NCT01297231</DOCNO>
	<brief_summary>Tamoxifen hormonal treatment breast cancer . It prevent recurrent disease decrease death . Tamoxifen give woman high risk breast cancer . These woman also commonly breast MRI monitor breast cancer . Some feature normal breast tissue visible breast MRI change depend patient hormonal status . It question hormonal change due tamoxifen see breast MRI . Pilot data suggest true . If tamoxifen cause change normal breast tissue MRI , study could do look whether breast MRI could tell u anything whether tamoxifen work . This study do see tamoxifen change normal breast tissue MRI . It also look factor like take anti-depressants gene type effect .</brief_summary>
	<brief_title>Prospective Analysis Changes Background Parenchymal Enhancement ( BPE ) Amount Fibroglandular Tissue Breast MRI</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>Females stage 03 breast cancer plan breast MRI within 1 year prior start tamoxifen Premenopausal status define intact ovary still menstruate Clinical MRI followup plan MSKCC MCKCC regional facility Willing able undergo study procedure Contraindication breast MRI ( noncompatible cardiac pacemaker intracranial vascular clip , allergy Gadolinium ) Bilateral breast cancer treatment : History plan bilateral breast irradiation History plan bilateral mastectomy Bilateral breast cancer History unilateral mastectomy radiation treatment contralateral breast cancer Taking chemo hormonal therapy time baseline breast MRI Estrogen progesterone receptor negative breast cancer GFR le GFR &lt; 30 mL/min/1.73m2 Postmenopausal woman Pregnant and/or nurse woman Less 21 year age</criteria>
	<gender>Female</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>fibroglandular tissue</keyword>
	<keyword>tamoxifen</keyword>
	<keyword>MRI</keyword>
	<keyword>Background Parenchymal Enhancement</keyword>
	<keyword>10-217</keyword>
</DOC>